A Phase 2 interventional study of SPY001 and SPY002 in Ulcerative Colitis, Inflammatory Bowel Diseases and Colitis, sponsored by Spyre Therapeutics, Inc.. Enrolling by invitation at 100 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Spyre Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Germany, Austria, Brazil, Mexico, Chile, Turkey (Türkiye)
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 221 studies in Colitis, Ulcerative with a site in Poland — 36 open to participants now, 65 under way, 31 of them phase 3. Colitis, Ulcerative · Poland.
Among the 221 studies in Colitis, Ulcerative with a site in Poland, this one is the 34th largest by planned enrollment of the 215 interventional ones that give a count, is one of 12 that started in 2026, is one of 104 in phase 2, reaches primary completion later than 52 of the 64 other live ones, and was the 219th registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →36 of the 221 studies in Colitis, Ulcerative with a site in Poland are open now. Recruiting first, the newest first:
Palisade Bio · Sites in Poland, United States, Canada and 9 more countries
Ages 18–75
Hoffmann-La Roche · Sites in Poland, United States, Belgium and 2 more countries
Ages 18–60
Pfizer · Sites in Poland, United States, Australia and 7 more countries
Ages 2–11
Janssen Research & Development, LLC · Sites in Poland, United States, Argentina and 30 more countries
Ages 18+
Eli Lilly and Company · Sites in Poland, United States, Belgium and 7 more countries
Ages 18–80
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
221 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 116 · Phase 3 93 · Phase 4 4
First in 2005; this study’s year is marked. 12 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 645 is above the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 196 across the 215 interventional studies, 389 across the 6 observational. Of the 154 that completed or were terminated, 121 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
212 of 221 have an industry lead sponsor. The 10 most frequent:
Spyre Therapeutics, Inc. is the lead sponsor of 8 studies on the registry; 3 are open to participants now.
Spyre Therapeutics, Inc. has 2 studies filed under Colitis, Ulcerative — fewer than ten, so there is no comparison to draw.
21 of the studies in Colitis, Ulcerative with a site in Poland that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06589986Phase 3Hoffmann-La RocheA Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis | 2027-01-30 |
| NCT06260163Phase 3Janssen Research & Development, LLCA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis | 2027-02-10 |
| NCT04624230Phase 3PfizerEvaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis | 2027-03-17 |
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
Add all 21 to your calendar (.ics) → With an account.
Among the 221 studies in Colitis, Ulcerative with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, long-term extension (LTE) study in participants with ulcerative colitis (UC) from Study SPY123-201 (The SKYLINE-UC study).
This is a multicenter, long-term extension (LTE) study in participants with ulcerative colitis (UC) from Study SPY123-201 (The SKYLINE-UC study) who have completed Part A and are deemed to be receiving clinical benefit, completed Part B, or met escape criteria in Part B. The primary aim of this LTE study is to characterize the long-term safety of various investigational drugs, to offer participants the option to extend treatment if they are clinically benefiting, or if they have not achieved sufficient clinical benefit (particularly placebo insufficient responders), to offer the opportunity to receive investigational drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants must meet 1 of the following criteria from Study SPY123-201:
Exclusion Criteria:
Is on any of the following prohibited medications:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive SPY001
Drug: SPY001
Participants will receive SPY002
Drug: SPY002
Participants will receive SPY003
Drug: SPY003
Participants will receive SPY001
Drug: SPY001
Participants will receive SPY002
Drug: SPY002
Participants will receive SPY003
Drug: SPY003
Participants will receive SPY001 and SPY002
Drug: SPY001 · Drug: SPY002
Participants will receive SPY001 and SPY003
Drug: SPY001 · Drug: SPY003
Participants will receive SPY002 and SPY003
Drug: SPY002 · Drug: SPY003
Participants will receive SPY002
Drug: SPY002
Experimental
Also known as: SPY001-001
Experimental
Also known as: SPY002-091
Experimental
Also known as: SPY003-207
Percentage of participants who experienced an adverse event
Incidence of treatment-emergent adverse events (TEAEs) as measured over time.
Time frame: Week 96
Percentage of participants with endoscopic improvement
Percentage of participants with endoscopic improvement at Week 48 will be assessed. Endoscopic improvement based on the Mayo endoscopic subscore (ranging from 0 to 3). Higher score indicates more severe disease.
Time frame: Week 48
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Mar 2029, 32 months after the start.
Of 110 industry-sponsored phase 2 interventional studies under Colitis, Ulcerative, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 35. This study's planned 32 months is above that.
Counting every sponsor, half of 154 studies reached it within 28 months; a quarter within 22 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
Germany, Austria, Brazil, Mexico, Chile, Turkey (Türkiye)
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Spyre Therapeutics, Inc.